Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Emily C. O’Brien, PhD,

Slides:

Advertisements

Similar presentations

Validity of the LaFarge equation for estimation of oxygen consumption in ventilated children with congenital heart disease younger than 3 years—A revisit.

Advertisements

Rate-control versus Rhythm-control Strategies and Outcomes in Septuagenarians with Atrial Fibrillation Nasir Shariff, MD, Ravi V. Desai, MD, Kanan Patel,

Prevalence, characteristics, and predictors of early termination of cardiovascular clinical trials due to low recruitment: Insights from the ClinicalTrials.gov.

Atrial fibrillation and quality of life after pacemaker implantation for sick sinus syndrome: Data from the Mode Selection Trial (MOST) Kirsten E. Fleischmann,

An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist.

Ali Ahmed, MD, MPH, Gilbert J. Perry, MD, Jerome L. Fleg, MD, Thomas E

Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated.

Estimates of Current and Future Incidence and Prevalence of Atrial Fibrillation in the U.S. Adult Population Susan Colilla, PhD, MPH, Ann Crow, MLS,

The Adherence eValuation After Ischemic Stroke Longitudinal (AVAIL) Registry: Design, rationale, and baseline patient characteristics Cheryl Bushnell,

Paul D. Stein, MD, Fadi Matta, MD, Mary J. Hughes, DO

Neutral impact on systolic and diastolic cardiac function of 2 years of intensified multi- intervention in type 2 diabetes: The randomized controlled Asker.

Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population Richard K. Cheng, MD, MS,

Changes in mid-life fitness predicts heart failure risk at a later age independent of interval development of cardiac and noncardiac risk factors: The.

Evidence-based care in a population with chronic kidney disease and acute coronary syndrome. Findings from the Australian Cooperative National Registry.

Impact of weight reduction on pericardial adipose tissue and cardiac structure in patients with atrial fibrillation Hany S. Abed, BPharm, MBBS, PhD,

New-onset Atrial Fibrillation Predicts Heart Failure Progression

American Heart Journal

Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation Anh L. Bui, MD, Maria.

Prevalence and predictors of nonobstructive coronary artery disease identified with coronary angiography in contemporary clinical practice Manesh R.

American Heart Journal

National evaluation of adherence to β-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance Judith.

Differences and trends in stroke prevention anticoagulation in primary care vs cardiology specialty management of new atrial fibrillation: The Retrospective.

Patients’ time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry Sean D. Pokorney, MD, MBA,

Risk of an asthma exacerbation after bariatric surgery in adults

Role of the CHADS2 Score in Acute Coronary Syndromes

Renato D. Lopes, MD, PhD, Li Li, MS, Christopher B

Telemedicine Specialty Support Promotes Hepatitis C Treatment by Primary Care Providers in the Department of Veterans Affairs Lauren A. Beste, MD, MSc,

A Clinical Study of COPD Severity Assessment by Primary Care Physicians and Their Patients Compared with Spirometry Douglas W. Mapel, MD, MPH, Anand.

Trends in Comorbidity, Disability, and Polypharmacy in Heart Failure

Telemedicine Specialty Support Promotes Hepatitis C Treatment by Primary Care Providers in the Department of Veterans Affairs Lauren A. Beste, MD, MSc,

Volume 15, Issue 4, Pages (April 2018)

Nancy M. Albert, PhD, Gregg C. Fonarow, MD, William T

Systematic Review and Meta-analysis of Adverse Events of Low-dose Aspirin and Clopidogrel in Randomized Controlled Trials Kenneth R. McQuaid, MD, Loren.

Leslie R. Harrold, MD, MPH, Daniel Peterson, MS, Ashley J

Volume 14, Issue 5, Pages (May 2017)

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation Giulia Renda, MD, PhD, Marco.

Alexander M. Walker, MD, DrPH, Dimitri Bennett, MD, MPH Heart Rhythm

Alexander M. Walker, MD, DrPH, Dimitri Bennett, MD, MPH Heart Rhythm

Risk Factors for Work Disability in Severe Adult Asthma

Atrial Fibrillation Correction Surgery: Lessons From The Society of Thoracic Surgeons National Cardiac Database James S. Gammie, MD, Michel Haddad, MD,

Sabina Hunziker, MD, MPH, Jennifer Stevens, MD, MS, Michael D

Gregory Y.H. Lip, MD, Jonathan L. Halperin, MD, Hung-Fat Tse, MD, PhD

Age and Gender Differences in Quality of Care and Outcomes for Patients with ST- segment Elevation Myocardial Infarction Sripal Bangalore, MD, MHA, Gregg.

Rate-control versus Rhythm-control Strategies and Outcomes in Septuagenarians with Atrial Fibrillation Nasir Shariff, MD, Ravi V. Desai, MD, Kanan Patel,

Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease Renato D. Lopes, MD, MHS, PhD, Meena Rao, MD,

Colorectal cancer and atrial fibrillation: a case-control study

Are Atrial Fibrillation Patients Receiving Warfarin in Accordance with Stroke Risk? Peter J. Zimetbaum, MD, Amit Thosani, MD, Hsing-Ting Yu, MPH, Yan.

Truman J. Milling, MD, Alex C. Spyropoulos, MD

Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin Keitaro Senoo, MD, Marco Proietti,

Management of Major Bleeding Events in Patients Treated With Dabigatran for Nonvalvular Atrial Fibrillation: A Retrospective, Multicenter Review Truman.

Validation of the Pregnancy Asthma Control Test

John P. Vavalle, MD, MHS, Renato D. Lopes, MD, PhD, Anita Y

Sara K. Pasquali, MD, MHS, Jennifer S

Analysis of Upper Gastrointestinal Adverse Events Among Patients Given Dabigatran in the RE-LY Trial Peter Bytzer, Stuart J. Connolly, Sean Yang, Michael.

Atrial fibrillation complicating lung cancer resection

Jewlya Lynn, PhD, Sophie Oppenheimer, MS, MPH, Lorena Zimmer, MA

Michael Copland, MD, Paul Komenda, MD, Eric D

Volume 16, Issue 1, Pages e3-e16 (January 2019)

Change in Asthma Control Over Time: Predictors and Outcomes

The Management of Eosinophilic Esophagitis

Sarah C. Snow, MD, Gregg C. Fonarow, MD, Joseph A

Joseph A. Dearani, MD, Michael J. Ackerman, MD, PhD

M. Alan Brookhart, PhD, Jerry Avorn, MD, Jeffrey N

Ali Ahmed, MD, MPH, Michael W. Rich, MD, Michael Zile, MD, Paul W

Volume 8, Issue 3, Pages (March 2011)

Atrial fibrillation after esophagectomy is a marker for postoperative morbidity and mortality Sudish C Murthy, MD, PhD, Simon Law, MBBChir, MS, FRCSEd,

George L. Bakris, MD, John M. Burkart, MD, Eric D

An International Model to Predict Recurrent Cardiovascular Disease

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation Giulia Renda, MD, PhD, Marco.

Michelle C. Wallace, MD, James Jaggers, MD, Jennifer S

Presentation transcript:

Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Emily C. O’Brien, PhD, DaJuanicia N. Simon, MS, Larry A. Allen, MD, MHS, Daniel E. Singer, MD, MA, Gregg C. Fonarow, MD, Peter R. Kowey, MD, Laine E. Thomas, PhD, Michael D. Ezekowitz, MD, Kenneth W. Mahaffey, MD, Paul Chang, MD, Jonathan P. Piccini, MD, MHS, Eric D. Peterson, MD, MPH American Heart Journal Volume 168, Issue 4, Pages 487-494 (October 2014) DOI: 10.1016/j.ahj.2014.07.002 Copyright © 2014 The Authors Terms and Conditions

Figure 1 Factors associated with warfarin discontinuation.*. This figure displays factors associated with warfarin discontinuation over 12 months of follow-up. *Multivariable pooled logistic regression using generalized estimating equations. American Heart Journal 2014 168, 487-494DOI: (10.1016/j.ahj.2014.07.002) Copyright © 2014 The Authors Terms and Conditions

Figure 2 Factors associated with warfarin discontinuation among prevalent users. *This figure displays factors associated with warfarin discontinuation over 12 months among prevalent warfarin users. *Prevalent warfarin users defined as patients who had been taking warfarin for ≥1 year. †Multivariable pooled logistic regression using generalized estimating equations. American Heart Journal 2014 168, 487-494DOI: (10.1016/j.ahj.2014.07.002) Copyright © 2014 The Authors Terms and Conditions

Figure 3 Factors associated with event-related* discontinuation. This figure displays factors associated with event-related warfarin discontinuation over 12 months of follow-up. *Event-related reasons included allergy, pregnancy, comorbid illness, prior intracranial hemorrhage, and bleeding event. †Multivariable proportional odds model using generalized estimating equations. American Heart Journal 2014 168, 487-494DOI: (10.1016/j.ahj.2014.07.002) Copyright © 2014 The Authors Terms and Conditions